Clinical trial
Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma
NCT00042913 · Jonsson Comprehensive Cancer Center, Other · Unknown status
Key facts
| NCT number | NCT00042913 |
|---|---|
| Title | Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma |
| Official title | A Phase 2 Open Label, Randomized, Dose And Schedule Finding, Clinical Trial Of Immunotherapy With AMG 412 In Subjects With Diffuse Large B-Cell Non-Hodgkin's Lymphoma |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | epratuzumab |
| Start date | May 1, 2002 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: